Radioactive drug indicated for positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer with suspected metastasis
Ended Awarded Last action
- Contract number
- 36C26124N0182
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 21
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $718,135
Award facts
- Contract value 100% obligated
- $718,135.28 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$3,609 | |
| Original award | $721,744 |
About this award
The Department of Veterans Affairs (VA) awarded a Blanket Purchase Agreement (BPA) call worth $718,135.28 to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., for the provision of PYLARIFY (piflufolastat F-18), a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect and image prostate cancer lesions. The contract is not set aside and is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). Lantheus Holdings, Inc., the parent company of Progenics Pharmaceuticals, is the prime contractor and has established several significant Indefinite Delivery Vehicles (IDVs) with the VA and Defense Health Agency (DHA) for the procurement of radiopharmaceuticals and other specialized medical imaging products. The contract has a period of performance through September 30, 2024 and is a firm fixed-price agreement.
Quick answers
Who was awarded contract 36C26124N0182?
36C26124N0182 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 21 (Veterans Health Administration) on October 1, 2023.
How much is contract 36C26124N0182 worth?
The government has obligated $718,135 on 36C26124N0182.
Is contract 36C26124N0182 an order under another contract?
Yes. 36C26124N0182 is a BPA call under 36F79719D0170-36C26123A0025, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26124N0182 competed?
The extent of competition for 36C26124N0182 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award